- Home
- APLT vs INMB Comparison
APLT vs INMB Comparison
Compare APLT & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- INMB
- Stock Information
- Founded
- APLT 2016
- INMB 2015
- Country
- APLT United States
- INMB United States
- Employees
- APLT N/A
- INMB N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- INMB Health Care
- Exchange
- APLT Nasdaq
- INMB Nasdaq
- Market Cap
- APLT 128.0M
- INMB 103.1M
- IPO Year
- APLT 2019
- INMB 2019
- Fundamental
- Price
- APLT $0.65
- INMB $6.45
- Analyst Decision
- APLT Buy
- INMB Strong Buy
- Analyst Count
- APLT 7
- INMB 2
- Target Price
- APLT $6.10
- INMB $21.00
- AVG Volume (30 Days)
- APLT 7.5M
- INMB 377.7K
- Earning Date
- APLT 03-05-2025
- INMB 10-31-2024
- Dividend Yield
- APLT N/A
- INMB N/A
- EPS Growth
- APLT N/A
- INMB N/A
- EPS
- APLT N/A
- INMB N/A
- Revenue
- APLT N/A
- INMB $42,000.00
- Revenue This Year
- APLT N/A
- INMB N/A
- Revenue Next Year
- APLT $2,622.90
- INMB N/A
- P/E Ratio
- APLT N/A
- INMB N/A
- Revenue Growth
- APLT N/A
- INMB N/A
- 52 Week Low
- APLT $0.60
- INMB $4.32
- 52 Week High
- APLT $10.62
- INMB $14.74
- Technical
- Relative Strength Index (RSI)
- APLT 20.60
- INMB 63.48
- Support Level
- APLT $0.60
- INMB $5.82
- Resistance Level
- APLT $0.74
- INMB $6.83
- Average True Range (ATR)
- APLT 0.09
- INMB 0.55
- MACD
- APLT 0.21
- INMB 0.18
- Stochastic Oscillator
- APLT 13.53
- INMB 83.61
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.